Acute Congestive Heart Failure Induced by Rofecoxib

References

1. ↵
   Singh G. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: 31S–38S.

   OpenUrlCrossRefPubMed
2. ↵
   Ko D, Wang Y, Berger AK, Radford MJ, Krumholz HM. Nonsteroidal antiinflammatory drugs after acute myocardial infarction. Am Heart J 2002; 143: 475–81.

   OpenUrlCrossRefPubMedWeb of Science
3. Stables G, Lawrence CM. Management of patients taking anticoagulant, aspirin, non-steroidal anti-inflammatory and other anti-platelet drugs undergoing dermatological surgery. Clin Exp Dermatol 2002; 27: 432–5.

   OpenUrlPubMed
4. Knijff-Dutmer EA, Kalsbeek-Batenburg EM, Koerts J, van de Laar MA. Platelet function is inhibited by non-selective non-steroidal anti-inflammatory drugs but not by cyclo-oxygenase-2-selective inhibitors in patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 458–61.
5. ↵
   Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001; 110 Suppl 3A: 20S–27S.
6. Thatte L, Vaamonde CA. Drug-induced nephrotoxicity: the crucial role of risk factors. Postgrad Med 1996; 100: 83–4.

   OpenUrl
7. Murray MD, Brater DC. Renal toxicity of the nonsteroidal anti-inflammatory drugs. Annu Rev Pharmacol Toxicol 1993; 33: 435–65.

   OpenUrlPubMed
8. ↵
   Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999; 106: 13S–24S.

   OpenUrlCrossRefPubMed
9. Patrono C, Dunn MJ. The clinical significance of inhibition of renal prostaglandin synthesis. Kidney Int 1987; 32: 1–12.

   OpenUrlPubMedWeb of Science
10. ↵
    Perazella MA. COX-2 inhibitors and the kidney. Hosp Pract (Off Ed) 2001; 36: 43–6, 55–6.
11. ↵
    Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000; 35: 937–40.

    OpenUrlPubMedWeb of Science
12. ↵
    LeLorier J, Bombardier C, Burgess E, et al. Practical considerations for the use of nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2 inhibitors in hypertension and kidney disease. Can J Cardiol 2002; 18: 1301–8.

    OpenUrlPubMed
13. ↵
    Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247–55.

    OpenUrlCrossRefPubMedWeb of Science
14. ↵
    Whelton A, Maurath CJ, Verburg KM, Geis GS. Renal safety and tolerability of celecoxib, a novel cyclooxygenase-2 inhibitor [published erratum appears in Am J Ther 2000;7:341]. Am J Ther 2000; 7: 159–75.

    OpenUrlPubMed
15. ↵
    Ahmad SR, Kortepeter C, Brinker A, Chen M, Beitz J. Renal failure associated with the use of celecoxib and rofecoxib. Drug Safety 2002; 25: 537–44.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994; 121: 289–300.

    OpenUrlPubMedWeb of Science
17. ↵
    Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520–8.

    OpenUrlCrossRefPubMedWeb of Science
18. ↵
    FitzGerald GA, Patrono C, The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 2001; 345: 433–42.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    Rofecoxib package insert. Whitehouse Station (NJ): Merck & Co.; 2002.
20. ↵
    Celecoxib package insert. New York: Pfizer; 2002.
21. ↵
    Whelton A, Fort JG, Puma JA, et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients [published erratum appears in Am J Ther 2001;8:220]. Am J Ther 2001; 8: 85–95.

    OpenUrlCrossRefPubMed
22. ↵
    Curhan GC, Willett WC, Rosner B, Stampfer MJ. Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med 2002; 162: 2204–8.

    OpenUrlCrossRefPubMedWeb of Science
23. ↵
    Kozuh JL. NSAIDs & antihypertensives: an unhappy union. Am J Nurs 2000; 100: 40–2; quiz 43.

    OpenUrl
24. ↵
    Whelton A, White WB, Bello AE, et al. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002; 90: 959–63.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    Zhao SZ, Reynolds MW, Lejkowith J, Whelton A, Arellano FM. A comparison of renal-related adverse drug reactions between rofecoxib and celecoxib, based on the World Health Organization/Uppsala Monitoring Centre safety database. Clin Ther 2001; 23: 1478–91.

    OpenUrlCrossRefPubMedWeb of Science
26. ↵
    Gertz BJ, Krupa D, Bolognese JA, Sperling RS, Reicin A. A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents. Curr Med Res Opin 2002; 18: 82–91.

    OpenUrlPubMedWeb of Science
27. ↵
    Frishman WH. Effects of nonsteroidal anti-inflammatory drug therapy on blood pressure and peripheral edema. Am J Cardiol 2002; 89: 18D–25D.

    OpenUrlPubMedWeb of Science
28. ↵
    Woosley RL. Drug labeling revisions—guaranteed to fail? JAMA 2000; 284: 3047–9.

    OpenUrlCrossRefPubMedWeb of Science